Peptides having reduced toxicity that stimulate cholesterol efflux

US11434267B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• John K. Bielicki · San Ramon, US
• Jan Johansson · Stockholm, SE
• Waleed Danho · Del Mar, US

Key dates

• Filing date: Sep 10, 2020
• Grant date: Sep 6, 2022
• Expiry date: Sep 10, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/775
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.